Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GLOBAL BLOOD THERAPEUTICS, INC.

(GBT)
  Report
Real-time Estimate Cboe BZX  -  01:11 2022-09-30 pm EDT
68.15 USD   +0.12%
09/23Global Blood Therapeutics, Inc. : Other Events (form 8-K)
AQ
09/15GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
AQ
09/08GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Global Blood Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Raised to $68.50 From $60 Amid Pfizer Deal

08/09/2022 | 08:31am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
GLOBAL BLOOD THERAPEUTICS, INC. 0.12% 68.155 Delayed Quote.132.56%
PFIZER, INC. 0.60% 44.45 Delayed Quote.-25.22%
All news about GLOBAL BLOOD THERAPEUTICS, INC.
09/23Global Blood Therapeutics, Inc. : Other Events (form 8-K)
AQ
09/15GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
AQ
09/08GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Dise..
AQ
09/07Insider Sell: Global Blood Therapeutics
MT
08/31Global Blood Therapeutics Investor A : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
BU
08/19Insider Sell: Global Blood Therapeutics
MT
08/12Biotech stocks pin bounce back hopes on M&A boost
RE
08/10North American Morning Briefing: Caution -2-
DJ
08/10Pfizer spending spree filters to Biopharma
AQ
08/09Global Blood Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Ta..
MT
More news
Analyst Recommendations on GLOBAL BLOOD THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 282 M - -
Net income 2022 -306 M - -
Net cash 2022 173 M - -
P/E ratio 2022 -14,4x
Yield 2022 -
Capitalization 4 593 M 4 593 M -
EV / Sales 2022 15,7x
EV / Sales 2023 10,3x
Nbr of Employees 457
Free-Float 93,1%
Chart GLOBAL BLOOD THERAPEUTICS, INC.
Duration : Period :
Global Blood Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLOBAL BLOOD THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 68,07 $
Average target price 68,50 $
Spread / Average Target 0,63%
EPS Revisions
Managers and Directors
Ted W. Love President, Chief Executive Officer & Director
Jeffrey S. Farrow Chief Financial & Accounting Officer
Mark L. Perry Chairman
Kim Smith-Whitley Executive VP, Head-Research & Development
Nazila Habibizad Senior Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
GLOBAL BLOOD THERAPEUTICS, INC.132.56%4 593
MODERNA, INC.-53.51%46 189
LONZA GROUP AG-38.51%35 456
IQVIA HOLDINGS INC.-35.63%33 872
ALNYLAM PHARMACEUTICALS, INC.24.28%25 132
SEAGEN INC.-12.23%25 028